Navigation Links
Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP,Receptor Antagonist at the American College of Cardiology

NEW ORLEANS, March 28, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. presented Phase I data of its ADP receptor antagonist at the of Cardiology's (ACC) 56th Annual Scientific Session this week. Portola's reversible antiplatelet compound, PRT060128, appeared safe and well-tolerated in this study and achieved high-level platelet inhibition.

Portola presented the data in a poster session titled "First in Human Experience with PRT060128, a New Direct-acting, Reversible P2Y(12) Inhibitor for IV and Oral Use" which describes the single ascending dose (SAD) study of the oral formulation of PRT060128. In this study, dose dependent and full inhibition of ADP-induced platelet aggregation was achieved. In addition, following administration of PRT060128, inhibition of platelet aggregation was fully reversed within 24 hours post dosing. All doses of PRT060128 were well tolerated. There were no serious adverse events and no discontinuations due to an adverse event.

"Successful results from both our Phase I oral and intravenous studies build a strong foundation for advancing PRT060128 in the clinic," said Dan Gretler, MD, Portola's vice president of Clinical Development and Regulatory Affairs. "We will initiate our Phase II clinical program later this year to further study the differentiated properties of our ADP receptor antagonist."

Portola's ADP Receptor Antagonist

PRT060128 is an antiplatelet drug that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola has studied this compound in a robust Phase I clinical development program including single ascending dose and multiple ascending dose studies with the oral
'"/>




Page: 1 2

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
3. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:8/3/2015)... , Aug. 3, 2015  Celsion Corporation ... Company will host a conference call to discuss ... an update on its development programs for ThermoDox®, ... two newly acquired technology platforms, TheraPlas™ and TheraSilence™, ... EDT on Monday, August 10, 2015. To participate ...
(Date:8/3/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), the developer ... metabolic diseases and other gastrointestinal disorders, today announced that ... the Board of Directors, effective July 31, 2015.  Ms. ... the 2018 annual meeting or until her successor is ... in an executive capacity in the healthcare industry for ...
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
Breaking Medicine Technology:Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
... April 16, 2012 genae, a leading Contract ... industries, today announced that Catalina Trana, MD, has been appointed ... responsible for all clinical, safety and risk management related to ... Catalina, whose extensive clinical and research expertise will be of ...
... subsidiary of Eisai Inc., announced today that it has ... and efficacy of MORAb-004 in the treatment of metastatic ... MORAb-004 is a monoclonal antibody that specifically binds to ... is a randomized, double-blind, placebo-controlled study to assess the ...
Cached Medicine Technology:genae Appoints Chief Medical Officer 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer 3
(Date:8/3/2015)... ... August 03, 2015 , ... Social ... , AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive ... – an organization whose mission is to develop technology for the sake of ...
(Date:8/3/2015)... ... August 03, 2015 , ... The art of preparing and cooking food ... side at a young age, Nasreen Zereshki was extremely eager to cook Persian cuisine. ... cookbook Recipes from My Persian Kitchen with the world. , Since Americans tend to ...
(Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions ... Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New York, ... be accessed via the investor relations section of the Company’s website. , About AxoGen, ...
(Date:8/3/2015)... ... August 03, 2015 , ... It’s 25 miles from ... California’s northernmost and among its least visited State Parks. The volcanic area beneath ... outflow is at Ahjumawi Lava Springs, part of the Fall River Springs complex. ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from ... rooms in recent years, according to the American Dental Association. According to a study ... visits went from 1.1 million in a single year to 2.2 million a year. ...
Breaking Medicine News(10 mins):Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
... for their effects on fat development, researchers have discovered ... in mice without some of the side effects ... they pinpointed, known as harmine, was first isolated more ... ritual and medicinal preparations around the world, the team ...
... and neglect of young children in military families in Texas ... at Chapel Hill study shows, raising concerns about the impact ... the country. ,The study, published in the ... was designed by UNC School of Public Health researchers to ...
... imported fire ants (RIFAs), which have caused trouble in ... Virginia. Colonies of the tiny, highly aggressive insects have ... in recent years, have caught the attention of Virginia ... the increasing number of fire ant infestations. ...
... 800 poultry farms in the capital following an outbreak of ... Saturday. ,The deadly H5N1 bird flu ... two other farms the next day in Chak Shehzad, a ... Usmani. ,Several thousand chickens were killed by the ...
... 30 seconds, it rivals HIV and tuberculosis as the world's ... are under five years old. Now, just over 100 years ... Prize for finally proving that malaria is transmitted by mosquitoes, ... a significant breakthrough in the search for an effective vaccine. ...
... specific antigen (PSA) levels is the most significant predictor of ... published in the journal Cancer. ,The study ... (PSA Velocity) is more than 2 ng/ml/year, it is an ... ,According to the researchers, the new findings attain ...
Cached Medicine News:Health News:Fat Screen Delivers Plant-derived Chemical With Antidiabetic Effects 2Health News:Stress of Deployment Increases Risk of Child Abuse, Neglect in Military Families, UNC Study Shows 2Health News:Stress of Deployment Increases Risk of Child Abuse, Neglect in Military Families, UNC Study Shows 3Health News:Fire Ants are Emerging Nuisance for Virginians 2Health News:Fire Ants are Emerging Nuisance for Virginians 3Health News:Vaccine Hope for Malaria 2Health News:Scientists Identify the Most Significant Single Predictor of Aggressive Prostate Cancer 2
... After inserting a finger into comfortable ... on, and continuous measurement is performed., ... character height. In darker surroundings, back ... reading., ,Light weight, compact contour ...
... The Autocorr Pulse Oximeter with SAC (Serial ... patented software to extract SpO 2 , ... a new way. This cost-effective compact ... functions as standard features, and a data ...
... fourth in the Clarity Series is ... with 3 or 5 lead ECG, ... (Serial Autocorrelation) technology, and respiration. ... two user configurable traces. An ...
... BCI 3180 Pulse Oximeter is a cost-effective, ... 2 pulse rate and pulse strength ... This AC or battery powered unit ... alarm limits and up to 30 hours ...
Medicine Products: